Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure

NCT01252810 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT01252810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01252810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure
Lead sponsor
GE Healthcare
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2012
Enrollment
284 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal insufficiency, congestive heart failure, diabete mellitus